Novel Approaches to Target MECOM/EVI1 in AML

Recruiting N/A Interventional Study
AML, Adult
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
24 (estimated)
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * AML with MECOM or atypical 3q26 rearrangements. * Age ≥18. * Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: * None
Contacts

Paola Fazi

0670390528

p.fazi@gimema.it

CONTACT

Enrico Crea

0670390514

e.crea@gimema.it

CONTACT